Elena Mead

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

18h-index8.6kcitations72works1.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(53), Biomedical Ethics and Regulation(7), Advancements in Semiconductor Devices and Circuit Design(6), Nanowire Synthesis and Applications(6), Integrated Circuits and Semiconductor Failure Analysis(5)

Publications72 total

Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICU
Critical Care Medicine·2025
CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis
Blood·2025· 2 cited
CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients
Blood·2025
POSTER: TCL-1383 CXCL9 as a Biomarker in Adults With Malignancy-Associated Hemophagocytic Lymphohistiocytosis
Clinical Lymphoma Myeloma & Leukemia·2025
TCL-1383: CXCL9 as a Biomarker in Adults With Malignancy-Associated Hemophagocytic Lymphohistiocytosis
Clinical Lymphoma Myeloma & Leukemia·2025· 1 cited
New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma
Blood Advances·2025· 1 citedOpen Access
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma
Transplantation and Cellular Therapy·2025· 8 cited
Emapalumab for the Treatment of Toxicities Associated with CD19 CAR-T Cells in Adult Patients
Transplantation and Cellular Therapy·2025· 3 cited
Hyperferritinemia Syndromes and Their Clinical Impact in Lymphoma Patients Receiving CD19 CAR-T Treatment
Transplantation and Cellular Therapy·2025· 1 cited
Identification of Pre-Treatment Clinical Risk Factors Predictive of Inferior Survival and Increased Risk of Treatment Failure in CD19 Chimeric Antigen Receptor T Cell Recipients with Large B Cell Lymphoma.
Transplantation and Cellular Therapy·2024
471: CAR T-ASSOCIATED BACTEREMIA: A SINGLE-CENTER, FIVE-YEAR RETROSPECTIVE
Critical Care Medicine·2023
A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2
Blood·2023· 2 cited
Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival
Blood·2023· 4 citedOpen Access
IMMUNE EFFECTOR CELL ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS-LIKE SYNDROME: A FIVE-YEAR RETROSPECTIVE OF A NEWLY-DEFINED CRITICAL TOXICITY
CHEST Journal·2023Open Access
Point-of-care Ultrasound (POCUS) Program for Critical Care Nurse Practitioners and Physician Assistants in an Oncological Intensive Care Unit and Rapid Response Team
Journal of the American Association of Nurse Practitioners·2023· 11 cited
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
Nature Medicine·2023· 144 citedOpen Access
Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
2023Open Access
Supplementary Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
2023Open Access
Supplementary Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
2023Open Access
Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Bianca Santomasso(29), Miguel‐Angel Perales(27), Jae H. Park(20), Gunjan L. Shah(20), Craig S. Sauter(19), Renier J. Brentjens(17), Roni Shouval(17), Michael Scordo(16), Sergio Giralt(16), Elizabeth Halton(15), Martina Pennisi(15), Connie Lee Batlevi(15), Parastoo B. Dahi(14), Sean M. Devlin(13), M. Lia Palomba(12), Claudia Diamonte(11), Molly Maloy(11), Isabelle Rivière(9), Sham Mailankody(9), Mark B. Geyer(9)